Chemocentryx (CCXI) Return on Assets ROA from the third quarter of 2026 to third quarter of 2022 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemocentryx Inc.  (NASDAQ: CCXI)


Chemocentryx's ROA from the third quarter of 2026 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Chemocentryx's ROA in the third quarter of 2026?
Chemocentryx Inc. achieved a return on average assets (ROA) of 94.77 % in its third quarter of 2026, this is above CCXI's average return on assets of -25.28%.
Chemocentryx Inc. assets over the 12 months ending in its third quarter of 2026 are valued at $421 million

ROA has improved compared to 62.31% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 577 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 4662 to 4669.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Total Assets Change 7.25 % 1.27 % 4.18 % -8.47 % -15.2 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 399 258 350 -111 -133
Return On Assets (TTM) 94.77 % 62.31 % 84.9 % -27.16 % -31.87 %
CCXI's Total Ranking # 4669 # 4662 # 4903 # 3975 # 4005
Total Assets (TTM) in million 425 423 419 416 397
Seq. Total Assets Change 0.63 % 0.84 % 0.77 % 4.87 % -4.98 %
Seq. Net Income Change - - - - -

CCXI's 5 Years Annual ROA >> Back to CCXI Management Effectiveness >> Compare CCXI ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 231
Sector # 578
Overall # 4559

Return On Assets Statistics
High Average Low
11.71 %
-25.28 %
-61.44 %
(Dec 31 2017)   (Mar 31 2016)





Financial Statements
Chemocentryx's Assets $ 425 million CCXI's Balance sheet
Chemocentryx's Income $ 109 million Quarterly CCXI's Income Statement
CCXI's Income by Division See CCXI's Income by Division



Annual Return On Assets (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017
Y / Y Total Assets Change -58.28 % 361.18 % 14.06 % -3.18 % -53.71 %
Total Assets in million 402 964 209 183 189
Y / Y Net Income Change - - - - -
Net Income in million -132 -55 -55 -38 18
Annual Return On Assets -32.75 % -5.74 % -26.54 % -20.71 % 9.43 %

CCXI's 5 Years Annual ROA >> Back to CCXI Management Effectiveness >> Compare CCXI ROA to its Competitors



More Return On Assets Ratios
CCXI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CCXI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CCXI's Competitors
Subscribers only: Roa for Chemocentryx's Suppliers
Subscribers only: Return On Assets for CCXI's Customers

You may also want to know
CCXI's Roi CCXI's Inventory Turnover Ratio CCXI's Growth Rates CCXI's Dividend Comparisons
CCXI's Profitability Ratios CCXI's Asset Turnover Ratio CCXI's Dividend Growth
CCXI's Roe CCXI's Valuation Ratios CCXI's Financial Strength Ratios CCXI's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Elutia Inc   103.90 %
Arbutus Biopharma Corp  89.26 %
Exelixis Inc   63.88 %
Rigel Pharmaceuticals Inc  59.56 %
Advanced Biomed Inc.  58.19 %
Lensar Inc   46.55 %
Alnylam Pharmaceuticals Inc   46.08 %
Oramed Pharmaceuticals Inc  45.62 %
Elite Pharmaceuticals Inc   43.95 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Qhslab Inc   22.59 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Protalix Biotherapeutics inc   19.89 %
Electromed Inc   19.73 %

Date modified: 2026-11-14T07:54:22+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.